Patient Adherence Metrics: What Brand Managers Should Track

Patient adherence is one of the most commercially significant yet frequently misunderstood metrics in pharmaceutical brand management. Poor adherence costs the pharmaceutical industry an estimated $188 billion annually in lost revenue in the United States alone, and the World Health Organization has identified medication non-adherence as a top public health challenge. For brand managers, understanding which adherence metrics to track, how to calculate them accurately, and what benchmarks to aim for is essential for both commercial performance measurement and the design of effective patient support programs.

Why Adherence Measurement Matters for Brand Performance

Adherence directly impacts brand revenue, patient outcomes, and market access positioning. A patient who fills only 6 of 12 monthly prescriptions in a year generates 50% less revenue than a fully adherent patient. At the portfolio level, a 5 percentage point improvement in adherence across a brand's patient population can translate to millions of dollars in incremental annual revenue. Beyond direct financial impact, adherence data is increasingly used in value-based contracting negotiations with payers, making accurate measurement a strategic imperative.

The challenge for brand managers is that adherence is not a single metric but a family of related measures that capture different aspects of patient behavior. Choosing the wrong metric can lead to flawed conclusions about program effectiveness and misallocated resources.

The Core Adherence Metrics

Four primary metrics form the foundation of adherence measurement. Each captures a different dimension of patient behavior and is suited to different analytical purposes.

1. Medication Possession Ratio (MPR)

MPR measures the total days of medication supply a patient has obtained divided by the number of days in the observation period. It answers the question: "What proportion of the time did this patient have medication available?"

For example, a patient who fills three 30-day prescriptions over a 180-day period would have an MPR of (30 + 30 + 30) / 180 = 0.50, meaning they had medication available for 50% of the period. MPR can exceed 1.0 when patients fill prescriptions early or have overlapping supplies, which is one of its limitations as a metric.

Strengths: Simple to calculate, widely understood, available from pharmacy claims data. Limitations: Does not confirm actual medication consumption, can exceed 1.0, does not capture gaps between fills.

2. Proportion of Days Covered (PDC)

PDC is the CMS-preferred adherence metric and is considered the gold standard for adherence measurement in pharmaceutical research. Unlike MPR, PDC accounts for overlapping fills by counting each day only once, and it cannot exceed 1.0.

PDC calculation requires adjusting for early refills by shifting overlapping days forward. For example, if a patient fills a 30-day supply on day 1 and another 30-day supply on day 25 (5 days early), the second fill coverage starts on day 31, not day 25. This prevents double-counting and ensures PDC never exceeds 1.0.

The standard threshold for "adherent" is a PDC of 0.80 or higher, meaning the patient had medication available for at least 80% of the measurement period. This threshold is used by CMS for Star Ratings and by most pharmaceutical companies for internal reporting.

Strengths: Cannot exceed 1.0, accounts for overlapping fills, aligns with CMS methodology. Limitations: More complex to calculate, still does not confirm actual consumption.

3. Persistence

Persistence measures how long a patient continues to fill prescriptions without a significant gap. Unlike MPR and PDC, which measure the intensity of medication use within a period, persistence measures the duration of continuous therapy.

Persistence is typically measured as the time from the first fill (index date) to the first significant gap or discontinuation event. Common persistence endpoints include the percentage of patients still persistent at 6 months and 12 months, and the median time to discontinuation.

Strengths: Captures the timing of therapy discontinuation, clinically meaningful. Limitations: Requires defining a permissible gap (which introduces subjectivity), does not capture re-initiation after discontinuation.

4. Time-to-Discontinuation

Time-to-discontinuation is a survival analysis metric that measures the elapsed time from treatment initiation to the first gap that exceeds the permissible gap threshold. It provides a more nuanced view of persistence by showing not just whether a patient is persistent at a fixed timepoint but how quickly patients drop off.

This metric is particularly valuable for identifying when in the treatment journey patients are most at risk for discontinuation. Many therapies show the highest discontinuation risk in the first 90 days, with a secondary drop-off around 6 months. Understanding these patterns enables targeted intervention timing.

Adherence Benchmarks by Therapy Area

Adherence rates vary dramatically across therapeutic areas, driven by factors including disease chronicity, symptom visibility, side effect profiles, medication complexity, and patient demographics. The following benchmarks provide context for evaluating your brand's adherence performance.

Fill Pattern Analysis

Beyond aggregate adherence metrics, analyzing individual patient fill patterns provides actionable insights into the types of non-adherence behavior that are most prevalent in your patient population. Common fill patterns include:

Pattern Types

• Consistent adherent: Regular fills with minimal gaps. These patients maintain a PDC above 0.90 and represent your most engaged patient segment. Focus: retention reinforcement and brand advocacy.
• Early discontinuer: Stops filling after 1-2 prescriptions, often within the first 60 days. This pattern suggests initial barriers such as cost shock, side effects, or insufficient understanding of the therapy. Focus: early intervention at the 2-4 week mark.
• Gradual decliner: Progressively longer gaps between fills over time, eventually leading to discontinuation. This pattern may indicate growing dissatisfaction, waning motivation, or changing life circumstances. Focus: ongoing engagement and periodic check-ins.
• Intermittent filler: Irregular fill pattern with frequent gaps but periodic re-engagement. These patients may be cherry-picking doses, taking drug holidays, or facing intermittent access barriers. Focus: addressing specific barriers and simplifying the regimen.
• Seasonal filler: Regular fills during certain periods but gaps during others, often correlated with insurance renewal cycles, seasonal symptom variation, or scheduled treatment breaks. Focus: anticipatory support during known gap periods.

Calculating Adherence from Claims Data

For brand managers who have access to pharmacy claims data (through specialty pharmacy partnerships, longitudinal prescription data providers, or hub program data), the following step-by-step process provides a reliable adherence calculation methodology.

PDC Calculation Steps

1. Define the patient cohort: Identify all patients who filled at least two prescriptions for your brand within the measurement period. A minimum of two fills is required to calculate adherence meaningfully.
2. Set the index date: Use the date of the first fill as the index date. The observation period begins on this date.
3. Determine the observation period: Standard periods are 6 months and 12 months from the index date. Ensure the observation period end date does not extend beyond the data availability date.
4. Collect fill data: Extract all fill dates and days supply values for each patient during the observation period.
5. Calculate coverage days: For each fill, determine the coverage period (fill date to fill date + days supply - 1). Adjust overlapping coverage periods by shifting subsequent fills forward.
6. Compute PDC: Divide total unique coverage days by the number of days in the observation period.
7. Apply the adherence threshold: Classify patients as adherent (PDC ≥ 0.80) or non-adherent (PDC < 0.80).

Strategies for Improving Adherence

Understanding adherence metrics is only valuable if it drives action. The following strategies have demonstrated measurable adherence improvements in pharmaceutical settings.

Patient-Facing Interventions

• Digital adherence reminders: SMS and app-based reminders timed to refill windows improve PDC by 5-10 percentage points on average. The most effective programs send reminders 5-7 days before the expected refill date.
• Patient education at initiation: Comprehensive onboarding education during the first 30 days of therapy reduces early discontinuation by 15-25%. Focus on setting expectations for side effects, timeline for efficacy, and importance of persistence.
• Copay assistance optimization: Removing cost as a barrier through copay card programs and patient assistance funds improves adherence by 10-20 percentage points for patients with high out-of-pocket costs.
• Peer support programs: Connecting patients with trained peer mentors who share their condition experience improves long-term persistence by 8-15%.

Provider-Facing Interventions

• Adherence data sharing with prescribers: Providing physicians with their patients' adherence data (with appropriate consent) prompts clinical interventions that improve PDC by 5-12 percentage points.
• Prescriber education on common drop-off points: Equipping prescribers with data on when patients are most likely to discontinue enables proactive follow-up at those critical moments.
• Simplified prescribing protocols: Reducing the complexity of titration schedules and monitoring requirements can improve early adherence by 10-20%.

Building an Adherence Dashboard

Brand managers should establish a quarterly adherence dashboard that tracks the following key indicators to monitor brand health and program effectiveness:

• PDC at 6 and 12 months: Track overall and by patient segment (new vs. continuing, commercial vs. Medicare, by region).
• 12-month persistence rate: The percentage of patients who remain on therapy at 365 days from their index fill.
• Median time to discontinuation: Monitor trends over time to detect early warning signs of declining engagement.
• First-fill to second-fill conversion: The percentage of patients who fill a second prescription within 45 days of their first fill. This is the strongest early predictor of long-term adherence.
• Adherence by intervention cohort: Compare adherence metrics for patients enrolled in support programs vs. those who are not, to measure program impact.

Conclusion

Patient adherence measurement is both an art and a science. The metrics you choose to track, the calculation methodology you employ, and the benchmarks you compare against all influence the insights you derive and the actions you take. For most brand teams, a combination of PDC as the primary adherence metric, persistence as the primary duration metric, and fill pattern analysis for patient segmentation provides the most comprehensive and actionable view of adherence performance. By establishing rigorous measurement practices and connecting adherence data to patient support program design, brand managers can drive meaningful improvements in both patient outcomes and commercial performance.